Actos News

Drugmaker Takeda May Face Thousands of Actos Bladder Cancer Lawsuits
Wednesday, December 28, 2011

Asia's largest drug manufacturer Takeda Pharmaceuticals could be facing thousands of lawsuits in the United States stemming from a link between their diabetes drug Actos and bladder cancer. In June, a study showed that users of Actos, the world's highest-selling diabetes drug, were at an increased risk for developing bladder cancer. The link prompted France and Germany to pull Actos off the shelves. Actos made up roughly 27 percent of Takeda's revenue with sales of $4.8 billion last year. Takeda has not commented on how the lawsuits will affect profits or whether the company will be setting aside money for the impending litigation. Judges are deliberating where the high volume of Actos lawsuits will be consolidated.